Gilead Touts Catalyst-Rich 2024 Amid Sales Slump

The drug maker pointed to a variety of key trial readouts over the course of the year, including the pivotal study of its long-acting HIV PrEP injectable and Phase III updates for Trodelvy.

After Gilead Sciences, Inc.’s fourth quarter sales came in lower than expected and the company issued 2024 guidance that analysts found unexciting, the drug maker is pinning its hopes on a number of catalysts in virology and oncology that it anticipates throughout the year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

01 May 2025

• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.